Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial
Study context
- Population
- Patients with acute myocardial infarction (MI) (type 1, 2, 4b or 4c) and hemoglobin <10 g/dLplanned enrolment
- Participants
- 3,500 patients
- Planned comparison
- Liberal vs restrictive red blood cell (RBC) transfusion strategy
- Primary endpoint
- Composite of:
- All-cause death
- Recurrent MI
- Follow-up
- 30 days following randomization
Methodological detailsmulticentre, 144 centres in the US, Canada, France, Brazil, New Zealand and Australia, Contact at 30 days to assess clinical outcomes and at 180 days to ascertain vital status, Secondary end points: all-cause mortality at 30 days, recurrent adjudicated MI, and composite of all-cause mortality, nonfatal recurrent MI, ischemia-driven unscheduled coronary revascularization (PCI or CABG) or readmission for ischemic cardiac diagnosis within 30 days
- Multicentre
- 144 centres in the US, Canada, France, Brazil, New Zealand and Australia
- Contact at 30 days to assess clinical outcomes and at 180 days to ascertain vital status
- Secondary end points: all-cause mortality at 30 days, recurrent adjudicated MI, and composite of all-cause mortality, nonfatal recurrent MI, ischemia-driven unscheduled coronary revascularization (PCI or CABG) or readmission for ischemic cardiac diagnosis within 30 days
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial. Am Heart J. Published 20 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →